UNIFORM CONTROLLED SUBSTANCES – Amends existing law to provide that alkaloids found in or derived from Mitragyna speciosa shall be a Schedule I controlled substance.
House Bill 830 amends Idaho’s Uniform Controlled Substances Act to add alkaloids found in or derived from Mitragyna speciosa to Schedule I. Mitragyna speciosa is the plant commonly associated with kratom, and the bill also covers synthetic alkaloids, homologs, analogs, isomers, esters, ethers, salts, and related forms when possible under the chemical designation. In practical terms, the measure places these substances alongside other Schedule I drugs that are treated as having no accepted medical use under state law and are subject to the most restrictive controls.
The bill also includes an emergency clause and sets an effective date of July 1, 2026. Beyond the kratom-related change, the bill restates and maintains Idaho’s extensive Schedule I list, which includes many opioids, fentanyl-related substances, hallucinogens, depressants, stimulants, and synthetic cannabinoids. The text does not appear to create a new regulatory program; rather, it updates the controlled-substances schedule by adding the Mitragyna-derived alkaloids to the existing prohibited category.
If enacted, the bill would amend section 37-2705 of the Idaho Code, expanding Schedule I to expressly include Mitragyna speciosa alkaloids and related derivatives. That would affect criminal enforcement, drug possession and trafficking prosecutions, and any state-level regulation that relies on Schedule I classification. Individuals, retailers, distributors, and potentially manufacturers or importers of kratom-related products would face heightened legal risk under Idaho law.
There is no recorded committee transcript or vote history in the provided materials, so direct legislative debate is not available. Based on the bill’s referral by the State Affairs Committee and its emergency effective-date language, the measure appears to reflect a policy choice to move quickly on controlled-substance scheduling. The available context suggests a straightforward, enforcement-oriented proposal rather than a broadly negotiated compromise.
The main point of contention is likely the decision to classify Mitragyna speciosa alkaloids as Schedule I, which is a strong prohibition and may be viewed by supporters as a public-safety measure and by opponents as an overbroad restriction on kratom products. Potentially affected parties include kratom users, retailers, herbal supplement businesses, and advocates who argue the plant has uses that do not fit Schedule I treatment. No specific objections or amendments are documented in the provided record, so the precise lines of debate are not available.